8-K: Intelligent Bio Solutions Remains on Track for 2025 U.S. Launch of Fingerprint Drug Screening System

Intelligent Bio Solutions Inc. provides an update on its FDA clearance process for its Intelligent Fingerprint Drug Screening System, reaffirming its planned U.S. launch in 2025.

Summary

• Intelligent Bio Solutions Inc. is pursuing FDA clearance for its Intelligent Fingerprint Drug Screening System.
• The company submitted its 510(k) premarket notification to the FDA on December 18, 2024.
• The FDA classified the system as a Class II device, requiring a 510(k) premarket notification.
• The submission included performance data, validation studies, and a method comparison study demonstrating 94.1% accuracy.
• A pharmacokinetic (PK) study showed fingerprint sweat provides a reliable sample matrix for drug detection.
• The FDA has responded with an Additional Information (AI) request, pausing the 90-day review clock.
• The company is responding to the AI request to restart the review clock.
• The company plans to enter the multi-billion-dollar U.S. market in 2025 and pursue FDA clearance for additional drug classes.
• The company's full panel test is already widely adopted, with a presence in 19 countries and over 400 accounts globally.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company is on track for its U.S. launch and has demonstrated high accuracy in studies. However, the AI request from the FDA introduces some uncertainty.

Positives

• The company's FDA clearance process is progressing as expected.
• The system has demonstrated high accuracy (94.1%) in studies.
• The company has a global presence with its full panel test.
• The company is actively preparing for its U.S. launch in 2025.

Negatives

• The FDA has issued an Additional Information (AI) request, which pauses the review clock.
• The FDA clearance process can take three to six months or longer, which could delay the launch.

Risks

• The FDA may require additional data, further delaying the clearance process.
• The company's ability to successfully commercialize its drug and diagnostic tests is subject to risks and uncertainties.
• Securing regulatory approvals is not guaranteed.

Future Outlook

The company plans to enter the multi-billion-dollar U.S. market in 2025 and pursue FDA clearance for additional drug classes on its panel.

Management Comments

• Harry Simeonidis, President and CEO at INBS, stated that the submission of the 510(k) premarket notification to the FDA marked a pivotal step in bringing the Intelligent Fingerprint Drug Screening System to the U.S. market.
• Mr. Simeonidis also stated that the company appreciates the thoroughness of the FDA's process and remains confident in the strength of their data.

Industry Context

The announcement relates to the broader industry trend of developing rapid, non-invasive drug testing solutions. Competitors in this space include companies offering saliva-based or other point-of-care drug testing devices. The fingerprint-based approach offers a unique selling proposition.

Comparison to Industry Standards

• The 94.1% accuracy reported in the method comparison study is a key metric.
• Comparable companies in the drug testing space, such as Abbott and Roche, have similar accuracy requirements for their diagnostic tests.
• The 510(k) clearance pathway is a standard regulatory process for medical devices in the U.S.

Stakeholder Impact

• Shareholders are informed about the progress of the FDA clearance process.
• Potential customers in the U.S. market are informed about the upcoming launch of the drug screening system.
• Employees are informed about the company's plans for expansion.

Next Steps

• The company will respond to the FDA's Additional Information (AI) request.
• The company will continue to develop its plans to enter the U.S. market in 2025.
• The company will pursue FDA clearance for additional drug classes on its panel.

Key Dates

Keywords

Intelligent Bio Solutions, Fingerprint Drug Screening System, FDA clearance, 510(k) premarket notification, Drug testing, Opiate test system, Pharmacokinetic study